Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: punj, 27 Apr 2021 08:31
Last post: kentan, 25 Jun 2021 02:04
After nearly hitting $44 a week ago on promising news of clinical trials, Portage (PRTG:NASDAQ) yesterday dropped 25% from their overnight price to $25.95 on news of a public offering of 1 million new shares at $23.
Portage intends to use the gross proceeds of $23,000,000 before deducting underwriting
discounts and offering expenses (without giving effect to any exercise of the underwriters’ option
to purchase additional ordinary shares, if any), for the acceleration of its PORT-2 and PORT-3
clinical programs, to prepare the next products to enter the clinic, and for working capital and
other general corporate purposes.
Quite a bombshell with the offer price discounted so heavily.
https://www.portagebiotech.com/wp-content/uploads/2021/06/Portage_Pricing-6.24.2021-FINAL.pdf
Encouraging results of preliminary trial has sparked a rise on NASDAQ.
Has risen from a low of $26.54 (since listing on NASDAQ) on 25th May 2021 to close at a consolidated $39.00 last night (up 48.7% for the period).
We can expect some profit-taking before the continued rise upwards on promising results of trials ... $50+ is easily possible and expected.
Our only problem with selling is it is still by matched bargains, so the spread can be very large, but once volume increases there is the possibility to state a minimum realistic price for bids for larger packages of shares and hope they are bought.
https://finance.yahoo.com/news/portage-biotech-highlights-first-patient-130000034.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAFusa_aApTmEHWGxIrryguR5XSs6qr6B0fVm5sx8To6nXZ6r31V7jAVV9yFl6Jk-aANdw7v7sp4jpewUeqS9-fwL-yQkLb50bj3cTrCnsBmL-I8R3jscY_Ie9pxHgB2zNZNBn5w3SczNLufrQis9OCgpUVIqc_evX_t4Mwy6bM6T
"Precious-01 Study Trials" ... First posted on 8th April 2021
Started: punj, 27 Apr 2021 08:26
Last post: Jarcon, 19 May 2021 16:48
With regard to the delisting, anyone else having the following issue:
Shares are showing in my account (ii) with the prtg price/value attached, but if I try to sell any it's showing my holdings as zero instead of the shares I actually hold.
I assume it's a quirk due to the delist that will correct itself eventually, just wondering if it's affecting anyone else
thanks.
https://investingnews.com/news/biotech-investing/portage-biotech-announces-voluntary-delisting-from-the-canadian-securities-exchange/
Voluntary delisting from CSE on 21st April 2021 to concentrate on Nasdaq.
All CSE held shares will be consolidated on Nasdaq under the ticker "PRTG".
Started: Investor81, 11 Feb 2021 15:18
Last post: kentan, 16 Mar 2021 17:06
I have been informed by "Etoro" that they cannot deal Portage Biotech (PRTG) shares on NASDAQ as there is no specific bid and ask at the current volumes. As has been said before, they are mainly an over the counter share with matched bargains so is something Etoro are unable to do (at present) ... that is, until they issue more stock and become a fully-fledged share like Biohaven (BHVN) has become, with high daily liquidity.
Most of the recorded transactions so far for PRTG on NASDAQ are for parcels of 100 shares, but there is no indication of whether they are buys or sells.
SALV hopefully will re-list as soon as is practical. Rumor has it that an unlisted company is lined up, just a waiting game really.
Yes SALV has got value as pointed out of approx. 30p a share.
Not quite on Nasdaq topic but can someone clear my confusion please? I sold my Portage shares some time ago, but I also bought about 1800 SalvaRx shares . What happens to them.? Do they have any value at all? Would be grateful for help.
Many thanks
This shell has to be worth around 30p a share in Portage right now. Got 50k of these and very impatient now..lol
I am exploring the possibility of being able to deal in PRTG on NASDAQ via the "Etoro" trading platform with low expenses and easy transfer of proceeds to UK ...
Currently, "Etoro" doesn't recognise the newly listed PRTG ticker on NASDAQ, but shouldn't be long now before they update their system.
Then it will be possible to buy and sell PRTG, providing the spread isn't too large.
Whatever happens, you must download the W8-BEN form and submit it, to be able to realise proceeds to UK exempt from higher US tax charges.
Started: kentan, 4 Mar 2021 16:46
Last post: kentan, 4 Mar 2021 16:46
https://investingnews.com/news/biotech-investing/portage-biotech-divests-portage-pharmaceuticals-limited-to-juvenescence-ltd/
Reasons for the listing on NASDAQ starting to take shape.
Could be the start of the big moves planned by Jim Mellon & Co. ... leading to an IPO for Juvenescence on the NASDAQ and/or London market.
Started: Jarcon, 22 Feb 2021 18:06
Last post: kentan, 23 Feb 2021 12:24
If you want to buy American shares you need to send a completed W-8BEN form to your broker (normally they will be able to provide the form and show you how to complete it). If you don’t then your dividends and interest will suffer 30% withholding tax, rather than 15%, and some overzealous brokers may even keep back 30% of any sale proceeds if they haven’t got a W-8BEN.
You can reclaim the excess tax but be warned. This means dealing directly with America’s Internal Revenue Service so I’d recommend completing the W-8BEN to avoid having to make a reclaim. W-8BENs remain valid until the first 31 December that occurs after the third anniversary of you signing the form. So a form signed on 1 March 2021 would remain valid until 31 December 2024, and so on.
I hold the paper share certificate issued for the original number of shares I received in the sale to Portage, but this was before the 1 for 100 consolidation last Autumn. I take it I now have the reduced digitalised holding that will apply to the NASDAQ listing. The shares are normally held within a nominee account.
Apparently, should I wish to trade (sell) the shares as a UK investor, I will need a W-8BEN form to be completed and lodged with a stockbroker who deals in USA markets for which there is a registration fee to be paid (around £595).
Hopefully, we expect the SP to fly on admission, so would be prudent to have the necessary paperwork completed in time.
I think it will be done automatically by your broker. The previous conversions etc. have all been done by the broker, though I expect it might take a day or two to show in your account.
So will our Canadian shares be automatically replaced by NASDAQ registered ones come Thursday?
Started: punj, 1 Jan 2021 19:11
Last post: punj, 1 Jan 2021 19:11
Finished at US$19.50 (day's high) yesterday on volume of 10,500 shares traded.
At the close the "Ask" varied in a range between US$20.08 and US$28.01, so plenty of upside can be anticipated to break through the US$20 resistance point when trading resumes on Monday.
FFWD likely to follow suit on AIM.
Jim Mellon is sitting pretty at the start of the year with all his investments in demand and active ... let's hope he wakes SALV up from its slumber.
Last post: jesterman, 1 Jan 2021 15:01
AS we have had no communication from SALV, I did some digging and found that the company is languishing in the Isle of Man and has been administered by;-
Sophia Birchall - LJ Management (IOM) Limited
Commerce House
1 Bowring Road
Ramsay
Isle of Man, IM8 2LQ
Placebo,
Maybe worth you monitoring what is going on at BOU.L (following delisting and awaiting news of RTO).
Jim Mellon is busy with his new baby Agronomics (ANIC.L) involved in the development of synthetic meat products and Juvenescence, the anti-ageing technology where there has been a delay to its anticipated IPO caused by the current world pandemic and its impact on the financial situation.
He has a lot of balls in the air, so collaboration with others is key to making progress, SALV could be the vehicle that achieves this.
Thank you Kentan. I’ll keep an eye out for any further updates.
The last report said they were in ongoing negotiations (RTO?) to become involved with another company to return to a full listing. This has met delays due to the Covid situation and various regulatory conditions to be met.
Funnily enough, the same has been said by another suspended company, Bould Opportunities plc (BOU) who it has been confirmed are in advanced negotiations with a "cancer detection biotechnology company" ... could it be SALV? ... both have said the same and were delisted around the same time. Would be a coincidence.
Does anyone have any news regarding this company?
Started: kentan, 22 Oct 2020 09:21
Last post: 1971Bod, 23 Dec 2020 11:06
The website has been removed and it was on one of the early links. Along the lines of...we will seek an asset, if this doesn’t happen the shares will be passed on to Salv holders.
Value of those shares is now $8.5m!
1971Bod - where did you get that information from?
don't get me wrong, i'd be very happy if that's the case,
Just wondering if there's any confirmation
thanks
James
Of they don’t relist we get a share divi, more portage shares!!!
i meant salv
are we ever going to get anything from sale again or will it just show up as zero in my account forever haha ??
Started: kentan, 3 Dec 2020 15:07
Last post: kentan, 22 Dec 2020 11:41
Portage hit $15.0 on CSE yesterday, only small trades though on turnover of 2,350 shares.
Remember this was $8.85 between 4th & 9th November and has steadily risen since boosted by the November 30th financial statement and report.
Plenty of upside on what is being envisaged for 2021.
https://webfiles.thecse.com/sedar_filings/00008656/2011301547192136.pdf
Very detailed and informative.
MANAGEMENT’S DISCUSSION AND ANALYSIS
Prepared as of November 30, 2020
https://webfiles.thecse.com/sedar_filings/00008656/2011301546339474.pdf
Portage Biotech SP on CSE has risen to $13.25 since these reports ... and rising.
Started: Jarcon, 15 May 2020 11:52
Last post: nikxs, 17 Aug 2020 15:20
i just seen in my ii isa account my portage share are now showing value.
So because this is delisted, can it not list again as it’s over it’s 6 month period. Anyone have any info. Cheers.
Hi All,
First time posting here.
I am with ii and am awaiting my Portage shares also. I have had email correspondance with them on the potential to trade the shares via the platform. The most recent answer from them is that i can trade them on the CSE via ii, albeit it will have to be a telephone trade. The trade will also be subject to currency conversion as my ii account is an ISA.
However, I'm not convinced this response from ii is accurate as i had previously been told that i couldn't trade the shares on the CSE. And that seems to be the information others here have received.
Who knows!
I am on Telegram but could not find Quint's Portage 2 group, any idea of the correct username?
When is a Medallion Signature Guarantee required?
Generally, a Medallion Signature Guarantee is required when an owner wants to sell or transfer securities held in physical certificate form, including stocks or bonds. If the securities are held through a broker, the owner will not need to obtain a Medallion Signature Guarantee.
Started: kentan, 30 Jun 2020 15:58
Last post: kentan, 30 Jun 2020 15:58
https://webfiles.thecse.com/PR62620.pdf?BJd2bGH6VndhFMk8l5Svoe.938xNpofj
Results of meeting on 26th June 2020 ... annual meeting for re-election of directors and corporate finance placement.
Started: kentan, 22 Jun 2020 14:43
Last post: kentan, 22 Jun 2020 14:43
In the fast-moving Covid-19 biotech world, there are 2 Australian companies worth Jim Mellon & Co. getting involved with (as investors or JV's to increase their worldwide expansion). Both are early days and in the right area.
DIMERIX LTD .... ASX:DXB
Have just completed an AUD$5.8m placement by institutions towards their global Phase 3 Covid-19 trials.
https://stockhead.com.au/health/institutions-back-hotshot-dimerix-for-covid-19-study/
CYNATA THERAPEUTICS ... ASX:CYP
Advanced Stem Cell studies for treatment of Covid-19 patients backed by USA University of Wisconsin-Madison technology.
https://stockhead.com.au/health/health-kick-cynatas-stem-cell-therapy-could-be-a-game-changer-for-covid-19-patients/
Portage Biotech & Salvarx would benefit both projects with exposure to UK & USA markets.
Started: kentan, 27 May 2020 03:44
Last post: jesterman, 27 May 2020 15:23
yes things are looking good!
Canadian TSX is one 'senior' market and American NASDAQ ; Could be one of those or both. As soon as an announcement is made I'm going to instruct ii to hold fire and await further news. I believe either of those markets may qualify for ISA to take either a bumper future divi or/ and a big capitol gain.
Not long before will find out
Portage Biotech have announced a share consolidation (reverse stock split) as approved by the BOD in January 2020, of 1 new share for every 100 held on 8th June 2020, subject to CSE approval.
They plan to offer a non-brokered private placement to raise US$10million at US$10 per share, post consolidation, with a weighted 20 day calculated price less a 10% discount.
Directors Dr Gregory Bailey and Jim Mellon have agreed to support the offer up to US$2million for any unsubscribed stock. This will be reduced if oversubscribed.
The funds will be available in tranches to enable acquisitions of new products and expansion of the existing portfolio.
Could this be a prelude to a listing on the US market?
Started: kentan, 14 May 2020 12:31
Last post: kentan, 26 May 2020 12:29
Portage Biotech closed on Monday at 15US cents with active trading, recovering from Friday's dip to 13.5US cents. Looks strong to challenge the last resistance point of 20US cents with the focus on the sector.
Maybe more news of a listing on the DOW now that their portfolio of Biotech companies need greater exposure to finance.
https://webfiles.thecse.com/PR5122020.pdf?o_uqrOY.nGzmOOfI9f3l7LNsYKOeXpuK
Portage Biotech has appointed a new Chief Financial Officer, Mr Allan L. Shaw, who replaces Mr Kam Shah, who retires after 7 years service to the companies.
Mr Shaw has a wealth of experience with over 20 years in the pharma/biotech sector.
This clears the decks for the next stage of the burgeoning acquisition programme that Portage has undertaken.
Portage rose to US$0.13 (touched US$0.14) on the news.
Started: Investor81, 15 May 2020 20:18
Last post: Investor81, 15 May 2020 20:18
Anyone know if this company is re-listing?
PORTAGE MAKES ADDITIONAL INVESTMENT IN STIMUNITY S.A.S, A PARIS-BASED CANCER IMMUNOTHERAPY COMPANY.
Invested $900,000
Shares up on CSE
To: US$0.14...
Portage Biotech rose slightly on the CSE to US$0.12 (up 14.29%) today on news:
Portage makes an additional US$700,000 investment in subsidiary company Saugatuck therapeutics after achieving proof of concept for NLG, one of its cancer treatment drugs.
NLG technology, invented in the lab of Dr Tarek Fahmy at Yale University and commercially
developed by our joint venture partner, Immunova, allows different combinations of drugs to
be encapsulated in a single nanomedicine and delivered selectively to the tumour
microenvironment, thus potentially minimizing systemic side-effects. Saugatuck which has
acquired an exclusive license from Yale University via Immunova for use of the NLG platform
for delivering DNA aptamers and certain aptamer-based combination products. Immunova is
developing a pipeline of NLG drugs focused on cytokine and other immune-modulating drugs.
Here are the latest trades recorded on The Canadian Stock Exchange for Portage Biotech:
https://thecse.com/en/listings/life-sciences/portage-biotech-inc
Average around 10USCents.
Haven't been informed by Barclays if they have notice of my share certificates yet, happy to wait if the value goes up as expected.
Last price of US$0.104 on the OTC market on Friday 24th April so maybe CSE price will appear today.
With plenty of upside in the offing I am not in a hurry to have my shares sold by Barclays... they were up to 20 US Cents not so long ago, so you can see why.
Its been a long wait, hopefully now i will receive my share certificates from with Barclays and Iii. I cant believe its almost 2 years since the de merger of Salv with Portage.
Great news this week with the tie up with Bristol Myerrs Squibb.
Started: Pesto, 12 Jul 2019 10:41
Last post: jesterman, 18 Apr 2020 08:24
Correction - CSE not OTC
Portage up and running again on the OTC ! as from 16th April. Hopefully now at least some of us will get our share certificates.
Not long now Kentan https://twitter.com/1971bod/status/1229798342089154561?s=21
In the OTC market, I can see Portage Biotech spiked to 18US Cents on Jan 24th and 20US Cents on Feb 6th. 2020 so this bodes well for when they are restored to the full market.
What isn't shown is the spread on the OTC market, which I assume will be quite large (depending on what buyers are prepared to pay).
At 15US Cents it gives a market cap of circa US$148million and at 20US Cents around US$200million.
Is Jim Mellon's "Juvenescence" part of Portage holdings or is it with SALV or FFWD? ... that will be a major game-changer.
1971Bod,
Here is the latest press release I can see published by Portage on their website:
https://www.portagebiotech.com/wp-content/uploads/2020/01/iOx-loan-and-CTO.pdf
You can see their application for the revocation of the cease trading order (CTO) submitted 13th January is still being considered by the Ontario Securities Commission. From reports at the end of December 2019, I thought they had been granted a temporary lifting of the ban on trading their shares, but I can see prices for PTGEF on the over the counter markets
... OTCMKTS:PGEF on Yahoo:
https://finance.yahoo.com/quote/PTGEF/
Currently 15US Cents ... up from 14.
My Barclays Smart Investor ISA portfolio shows the original holding for SALV and Portage at 18x their number. But the corporate action notice says these are to be sold as they do not comply with ISA rules and because SALV has delisted there is no value attached to them.
Agree with you, the whole scenario has been completely mismanaged by Barclays and will hold them to account once this is resolved. ... last time I had a problem with them they sent me a hamper as compensation ... but I would need more than that to compensate me for my loss and inconvenience this time (despite the total value of my Portage holding going up 50%).
Started: kentan, 4 Feb 2020 11:42
Last post: kentan, 4 Feb 2020 11:42
https://privatebank.barclays.com/news-and-insights/2019/november/the-race-for-a-breakthrough-in-longevity-biotech/?cid=ad03mm01soc_sc02ca07cr01co71te01
Could what the cash shell will be aimed at?
Thought Juvanescence was part of our portfolio with Portage Biotech.
Started: kentan, 25 Nov 2019 12:47
Last post: jesterman, 10 Jan 2020 12:05
Sorry 10th Jan; Today! We are now de-listed.
Waiting for an announcement imminent Re; a reverse takeover (if it happens)
10th of? Feb?
Ok so cancellation of SALV on the 10th and hopefully an announcement of a reverse takeover and a new listing.
Lets hope it's a good one!
Pesto; Just had a quick scan though Agronomics, interesting; I guess it will be about economies of scale. It would need to be cheaper than traditional meat farmed production to make any real impact, at least in the short to medium term.
My feeling is that Vegan alternatives will have a greater impact, again in the short to medium term and possibly be the main market leader. Early days but one to watch!
I am now wondering if Jim Mellon will do something slimier with SALV .......We will soon find out!
Just a final thought are any of you guys invested in Agronomics? I have been holding for about 8 weeks..
Started: Pesto, 31 Oct 2019 09:58
Last post: Pesto, 31 Oct 2019 09:58
Not sure if any of you guys are still viewing the posts here. Either way update below i received yesterday..
Dear
I wanted to write to you, further to my previous email, to provide you with another update on the SalvaRX Group Plc Corporate Action.
Regrettably, since my last email a Cease Trading Order (CTO) has been implemented by the company which has affected the registrars response regarding the re-registration of your Portage Biotech holding.
To keep you updated, we have been advised the stock is under a "Cease Trade Order" which means the asset cannot be traded on any exchange/market. On this basis, the registrar has rejected our request to re-register these holdings based on the CTO being active. I appreciate this is not the answer you were hoping for.
To explain, we challenged this with the Chief Financial Officer of Portage Biotech and managed to achieve sign off for the registrar to complete our re-registration request. On 23 October 2019, the registrar was checking with their internal compliance department and the request was not yet completed. Be assured, we've chased the registrar for updates and completing your request remains a priority for us.
The registrars have since advised they require a legal affidavit in order to progress with our request to re-register your Portage Biotech holding. We have therefore referred to our Legal Team to provide this on our behalf. Unfortunately, due to this new information provided by the registrar, we are unable to confirm when you shall receive your certificate.
That being said, I will continue to provide you updates, once available, until you are in receipt of your Portage Biotech holding.
Kind regards
Last post: Matador78, 26 Aug 2019 22:02
TORONTO, Aug. 26, 2019 /PRNewswire/ - Portage Biotech Inc. (PBT.U, OTC Markets: PTGEF) ("Portage" or the "Company") is providing an update on the status of the filing of its audited annual financial statements for the year ended March 31, 2019, accompanying management discussion and analysis together with the related certifications (collectively, the "Annual Filings"). The Annual Filings have been completed but are currently being reviewed for quality assurance by the Company's auditors. The Company anticipates that final approval and posting of the Annual Filings on www.sedar.com will be completed shortly.
As a consequence of the delay in the preparation of the Annual Filings, the Company also announces that the filing of its financial statements for the three-month period ended June 30, 2019, accompanying management discussion and analysis together with the related certifications (the "Interim Filings") will also be delayed and not released as required on August 29, 2019. The Company expects the Interim Filings to be filed shortly after the Annual Filings are filed.
On August 2, 2019, the Ontario Securities Commission (the "OSC") issued a Failure-to-File Cease Trade Order against the Company on (the "FFCTO") as a result of the Company's failure to the Annual Filings by the prescribed filing deadline of July 29, 2019, as required by National Instrument 51-102, Continuous Disclosure Obligations, and NI 52-109, Certification of Disclosure in Issuers' Annual and Interim Filings, respectively. The FFCTO remains in place.
The Company reports that since its news release of July 31, 2019, there have been no material changes regarding the information contained in that news release. Further, there is no other material information concerning the affairs of the Company that has not been generally disclosed.
Last post: Dougie999, 16 Jul 2019 16:56
i have spoken to II and they have said that once the share certificates have been sent out you can wait until portage deal with a market they deal in and they will arrange free of charge or deposit them with a different broker. when will we see some action here??
Started: mike84400, 9 Jul 2019 12:58
Last post: Quint, 10 Jul 2019 17:14
Website says. Stock-portage assisted sale. Type-takeover
I’m with x-o. Yep they did it without my say so.
You sold them by telling them to do it, they didn’t do it automatically did they without your say so
Good afternoon Mike,
who did you hold with that enabled you to sell?
(if you don't mind me asking)
Thanks
Shares have been sold, 100% profit.
Last post: Lowtown, 26 Jun 2019 17:20
Many thanks - looks good!
Assuming no updates the holdings from Portage website are:-
Sentien 5.06%
Stimunity 27%
Eygen 100%
IOX 60.49%
Nikonal 33%
Rift 34.99%
Saugatuck 70%
Intensity 9.2%
Anyone know the latest portfolio constituents %, particularly PTGEF/Intensity, thanks.
Last post: 1971Bod, 25 Jun 2019 20:04
Bit quiet here but that’ll change in the next fortnight or so. Plenty of chat on twit her under $ptgef for those interested.
Have announced clinical collaboration with Merck